The Hopkinton, Mass.-based orthopedics firm says it's ahead of schedule with the Acadia study of its facet joint reconstruction device.
Facet Solutions Inc. enrolled the 100th patient in the Acadia investigational device exemption study of its lumbar spinal stenosis treatment.
President and CEO Geoff Pardo said the company is head of schedule with the trial, which will examine the efficacy of its Acadia posterior stabilization system. The device is a joint reconstruction device designed to match the size and shape of the facet joint to provide lumbar spinal stenosis patients with pain relief, normal motion and stability. The procedure involves the replacement of diseased posterior spinal joints with an anatomic implant.
Last week, MassDevice broke the news that Facet snapped up defunct Archus Orthopedics' intellectual property for an undisclosed amount. The company also closed a $3.6 million in a debt offering, according to a regulatory filing.
Warren Watson, a 30-year Medtronic Inc. employee with family connections to founder Earl Bakken, is...
Quidel Corp. wins Food & Drug Administration 510(k) clearance for its chorionic gonadotropin-...
Ann Arbor, Mich.-based HistoSonics Inc. snags former Food & Drug Administration commissioner Dr....
The Food & Drug Administration releases a list of the medical devices it granted 510(k) clearance...
A federal grand jury indicts former Spectranetics CEO John Schulte, two other executives and a...